Carolyn A. Fairbanks

Carolyn A. Fairbanks

Auto-generated profile, based on publicly available information

Carolyn A. Fairbanks

Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota; Department of Neuroscience, School of Medicine, University of Minnesota, Minneapolis, Minnesota; Department of Pharmacology, School of Medicine, University of Minnesota, Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Molecular Pain
Verified
Journal Article
Open access
LVLucy Vulchanova
Lucy Vulchanova
DSDaniel J Schuster
Daniel J Schuster
LBLalitha R Belur
Lalitha R Belur
MRMaureen S Riedl
Maureen S Riedl
KPKelly M Podetz-Pedersen
Kelly M Podetz-Pedersen
CFCarolyn A Fairbanks
Carolyn A Fairbanks
Background: Neuronal transduction by adeno-associated viral (AAV) vectors has been demonstrated in cortex, brainstem, cerebellum, and sensory ganglia. Intrathecal delivery of AAV serotypes that transduce neurons in dorsal root ganglia (DRG) and spinal cord offers substantial opportunities to 1) further study mechanisms underlying chronic pain, and 2) develop novel gene-based therapies for the treatment and management of chronic pain using a non-invasive delivery route with established safety margins. In this study we have compared expression patterns of AAV serotype 5 (AAV5)- and AAV serotype 8 (AAV8)-mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Results: Intravenous mannitol pre-treatment significantly enhanced transduction of primary sensory neurons after direct lumbar puncture injection of AAV5 (rAAV5-GFP) or AAV8 (rAAV8-GFP) carrying the green fluorescent protein (GFP) gene. The presence of GFP in DRG neurons was consistent with the following evidence for primary afferent origin of the majority of GFP-positive fibers in spinal cord: 1) GFP-positive axons were evident in both dorsal roots and dorsal columns; and 2) dorsal rhizotomy, which severs the primary afferent input to spinal cord, abolished the majority of GFP labeling in dorsal horn. We found that both rAAV5-GFP and rAAV8-GFP appear to preferentially target large-diameter DRG neurons, while excluding the isolectin-B4 (IB4) -binding population of small diameter neurons. In addition, a larger proportion of CGRP-positive cells was transduced by rAAV5-GFP, compared to rAAV8-GFP. Conclusions: The present study demonstrates the feasibility of minimally invasive gene transfer to sensory neurons using direct lumbar puncture and provides evidence for differential targeting of subtypes of DRG neurons by AAV vectors.

1 December 2019 in Comparative Medicine
Verified
Journal Article
Closed access
CLChristina M Larson
Christina M Larson
GWGeorge L Wilcox
George L Wilcox
CFCarolyn A Fairbanks
Carolyn A Fairbanks
Pain is a clinical syndrome arising from a variety of etiologies in a heterogeneous population, which makes successfully treating the individual patient difficult. Organizations and governments recognize the need for tailored and specific therapies, which drives pain research. This review summarizes the different types of pain assessments currently being used and the various rodent models that have been developed to recapitulate the human pain condition.

1 January 2015 in Molecular Pain
Verified
Journal Article
Open access
JGJean-Marc G Guedon
Jean-Marc G Guedon
SWShaogen Wu
Shaogen Wu
XZXuexing Zheng
Xuexing Zheng
CCCaroline C Churchill
Caroline C Churchill
JGJoseph Charles Glorioso
Joseph Charles Glorioso
SHShuanglin Hao
Shuanglin Hao
The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao).

3 December 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TWTate N. Winter
Tate N. Winter
WEWilliam F. Elmquist
William F. Elmquist
CFCarolyn A. Fairbanks
Carolyn A. Fairbanks

1 August 2017 in Human Gene Therapy
Verified
Journal Article
Closed access
KLKanut Laoharawee
Kanut Laoharawee
KPKelly M. Podetz-Pedersen
Kelly M. Podetz-Pedersen
TNTam T. Nguyen
Tam T. Nguyen
LELaura B. Evenstar
Laura B. Evenstar
KKKelley F. Kitto
Kelley F. Kitto
RMR. Scott McIvor
R. Scott McIvor
Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked recessive lysosomal disorder caused by defective iduronate-2-sulfatase (IDS), resulting in accumulation of heparan sulfate and dermatan sulfate glycosaminoglycans (GAGs). Enzyme replacement is the only Food and Drug Administration–approved therapy available for MPS II, but it is expensive and does not improve neurologic outcomes in MPS II patients. This study evaluated the effectiveness of adeno-associated virus (AAV) vector encoding human IDS delivered intracerebroventricularly in a murine model of MPS II. Supraphysiological levels of IDS were observed in the circulation (160-fold higher than wild type) for at least 28 weeks post injection and in most tested peripheral organs (up to 270-fold) at 10 months post injection. In contrast, only low levels of IDS were observed (7–40% of wild type) in all areas of the brain. Sustained IDS expression had a profound effect on normalization of GAG in all tested tissues and on prevention of hepatomegaly. Additionally, sustained IDS expression in the central nervous system (CNS) had a prominent effect in preventing neurocognitive deficit in MPS II mice treated at 2 months of age. This study demonstrates that CNS-directed, AAV9 mediated gene transfer is a potentially effective treatment for Hunter syndrome, as well as other monogenic disorders with neurologic involvement.

15 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CWCarrie L. Wade
Carrie L. Wade
PKPerry Krumenacher
Perry Krumenacher
KKKelley F. Kitto
Kelley F. Kitto
CPCristina D. Peterson
Cristina D. Peterson
GWGeorge L. Wilcox
George L. Wilcox
CFCarolyn A. Fairbanks
Carolyn A. Fairbanks
The development of opioid addiction in subjects with established chronic pain is an area that is poorly understood. It is critically important to clearly understand the neurobiology associated with propensity toward conversion to addiction under conditions of chronic pain. To pose the question whether the presence of chronic pain influences motivation to self-administer opioids for reward, we applied a combination of rodent models of chronic mechanical hyperalgesia and opioid self-administration. We studied fentanyl self-administration in mice under three conditions that induce chronic mechanical hyperalgesia: inflammation, peripheral nerve injury, and repeated chemotherapeutic injections. Responding for fentanyl was compared among these conditions and their respective standard controls (naïve condition, vehicle injection or sham surgery). Acquisition of fentanyl self-administration behavior was reduced or absent in all three conditions of chronic hyperalgesia relative to control mice with normal sensory thresholds. To control for potential impairment in ability to learn the lever-pressing behavior or perform the associated motor tasks, all three groups were evaluated for acquisition of food-maintained responding. In contrast to the opioid, chronic hyperalgesia did not interfere with the reinforcing effect of food. These studies indicate that the establishment of chronic hyperalgesia is associated with reduced or ablated motivation to seek opioid reward in mice.